Company: RGNT
Filing Date: 2025-09-30
Form Type: F-1/A
Source: 0001213900-25-093302
Chunk: 192

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-09-30
Form: F-1/A
Chunk 192
---
 2024, we entered into loan agreements, or the 2024 Loan Agreements pursuant to which we obtained a loan in the aggregate
amount of $150,000 from certain lenders, including Dr. Ehud Geller, the chairman and a member of our board of directors and SCP Vitalife
Partners (which is affiliated with our director, Jeff Dykan). In October 2024, we amended the 2024 Loan Agreements pursuant to which
the 2024 Loan Agreements have been extended until August 31, 2025, shall bear interest at 8% per annum until maturity commencing as of
September 1, 2024, and we agreed to pay the lenders at maturity an additional aggregate amount of $50,000 as a risk premium. Furthermore,
upon the occurrence of a Qualified IPO, the 2024 Loan Agreements lenders, shall be granted warrants to purchase such number of Ordinary
Shares equal to two times their respective loan amount in addition to a risk premium based on a price per share equal to 75% of the lowest
price per share of the Company’ Ordinary Shares during the first five trading days following the consummation of such initial public
offering. On March 31, 2025, we and the lenders entered into an amendment to the 2024 Loan Agreement to extend the maturity date until
the earlier of August 31, 2025, or the consummation of an IPO. On July 1, 2025, we entered into an amendment to the 2024 Loan Agreements
such that the 2024 Loan Agreement lenders shall be granted warrants to purchase up to 61,539 Ordinary Shares following the consummation
of this offering. During September 2025, the 2024 Loan Agreements have been extended until November 30, 2025.

<div align='center'>116</div>

On December 1, 2024,
we entered into a loan agreement with our Chief Executive Officer, or the December 2024 Loan Agreement, according to which accrued
payroll salary owed to him in the aggregate amount of $117,000 plus VAT was converted into a loan. The loan amount bears interest at
an 8% annual rate, and is due upon the earlier of the consummation of this offering or March 31, 2025. In addition, upon maturity,
the Company will pay to our Chief Executive Officer an aggregate risk premium equal to 30% of the loan